2025-523726-40-00RecruitingPhase 3
A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
F. Hoffmann-La Roche AG27 sites in 4 countries54 target enrollmentStarted: June 16, 2026Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 54
- Locations
- 27
Study Overview
Brief Summary
To evaluate the suitability of the on-body delivery system (OBDS) for high concentration (HC) subcutaneous (SC) ocrelizumab administration by the participant or their lay caregiver
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 18-65 years at the time of signing Informed Consent Form
- •Willing and able to receive injections using the OBDS, as either a self-injection or administered by a lay caregiver For participants who are willing to complete self-injection: deemed by the healthcare provider to be able to do the injection based on motor and cognitive function
- •For female participants of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for 6 months after the final dose of ocrelizumab
- •For female participants without childbearing potential: Female participants may be enrolled if postmenopausal
- •Currently being treated with ocrelizumab: At least one prior dose of ocrelizumab 600 mg IV or 920 mg SC Note: The first dose of ocrelizumab in this study will be administered approximately 6 months (± 1 month) after a previous (pre-study) ocrelizumab dose (and may not be administered earlier than 5 months after the last pre-study ocrelizumab dose)
- •Diagnosis of MS according to the revised McDonald 2024 criteria (Montalban et al. 2025) or the most current published revision of the McDonald criteria at the time of study start
Exclusion Criteria
- •Participant does not have reliable and consistent access to communication (e.g., telephone/mobile phone)
- •Participant resides in a location that, in the investigator's opinion, does not allow for timely access to an emergency medical facility
- •Pregnant or breastfeeding, or intending to become pregnant during the study or within the time frame in which contraception is required
- •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- •Sensitivity or intolerance to any ingredient (including excipients) of ocrelizumab
- •Sensitivity or intolerance to acrylic
Arms & Interventions
Ocrevus, Ocrelizumab
Test
Intervention: Ocrevus, Ocrelizumab (Drug)
Investigators
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
Study Sites (27)
Loading locations...
Similar Trials
Recruiting
Phase 2
A phase 1/2 study of SLN124 in patients with Polycythemia VeraPolycythemia Vera2023-503544-13-00Silence Therapeutics PLC68
Recruiting
Phase 2
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias. Various doses of SNDX-5613 will be investigated.2024-513759-34-00Syndax Pharmaceuticals Inc.34
Not yet recruiting
Unknown
Post-Market Clinical follow-up study to evaluate safety and performance of Altius Buechel Pappas Primary Total Knee Replacement SystemCTRI/2025/04/085046TTK Healthcare Ltd (Ortho Division)200
Recruiting
Phase 3
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer.2024-519654-37-00Bicara Therapeutics Inc.191
Not yet recruiting
Not Applicable
Oxygen Delivery Index (ODIN) StudyCardiogenic ShockHeart FailureNCT07601828NYU Langone Health30